885 - The efficacy of gemcitabine-based chemoradiotherapy for the definitive treatment of locally-advanced bladder cancer

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Urothelial Cancers
Surgical Oncology
Biological Therapy
Radiation Oncology
Presenter Meral Kurt
Authors M. Kurt1, H. Ozturk2, S. Cetintas3, E. Kurt4, L. Ozkan3
  • 1Radiation Oncology, Uludag University School of Medicine, 16059 - BURSA/TR
  • 2Radiation Oncology, Yunus Emre Hastahanesi, Eskisehir/TR
  • 3Radiation Oncology, Uludag University, Bursa/TR
  • 4Medical Oncology, Uludag University, BURSA/TR



The aim of the present study was to investigate the efficacy and the tolerability of gemcitabine-based chemoradiotherapy (CRT) for the definitive treatment of locally-advanced bladder cancer.


Patients with the diagnosis of locally-advanced, transitional cell bladder cancer, who had been treated with gemcitabine-based CRT at the Radiation Oncology department of the Uludag University between January 2005 and January 2009, were enrolled in this retrospective analysis. After maximal transurethral resection of tumor, three-dimensional radiotherapy (RT) was administered at an initial dose of 45 Gy to the primary tumor site plus regional lymphatics followed by a 20 Gy boost to the whole bladder with additional 2 cm margins (1.8 Gy daily fractions, five days a week). All patients received weekly gemcitabine at a dose of 350 mg/m2 on Mondays during the course of RT. Response evaluations were performed every three months by systoscopic examinations and appropriate radiologic studies.


A total of 20 patients were entered into the study. There were 18 male and 2 female with a median age of 72 (range: 40–78). The median disease-free survival was 35,0 ± 8,2 months (95% CI: 18,7–51,2), and the median overall survival was 37,0 ± 4,4 (95% CI: 28,3–45,7). Acute treatment-related grade ¾ hematologic toxicities were seen in 4 patients (20%). Although 3 patients (15%) exhibited grade ½ gastrointestinal toxicities, there were no grade ¾ non-hematologic toxicities.


Gemcitabine-based definitive CRT seems to be effective and tolerable treatment option for the treatment of locally-advanced bladder cancer.


All authors have declared no conflicts of interest.